Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).